Drugs / RPH-002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07435311 | Jun 2020 → Jul 2024 | head and neck squamous cell carcinoma | R-Pharm | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07435324 | Aug 2024 → Sep 2025 | head and neck squamous cell carcinoma | R-Pharm | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RPH-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07435324 ↗ |
| Route | Intravenous | “RPH-002 is administered IV once weekly.” NCT07435311 ↗ |